Getinge reported soft Q1 22 numbers, missing estimates across the board and sending the stock down >15%.
Sales were down 6.4% on an organic basis, attributable to acute care therapies (-14.3%) and supply chain challenges. The impact of multiple headwinds was felt on operating margins too (-350bps).
Encouragingly, the FY 22 outlook (upper end of 4-6% organic growth) was maintained.
We will be trimming our estimates to factor in the soft Q1 showing, which should be partly offset by stronger H2 ....
27 Apr 2022
Q1 22: Derailed by supply chain disruptions
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q1 22: Derailed by supply chain disruptions
- Published:
27 Apr 2022 -
Author:
Virendra Chauhan -
Pages:
3
Getinge reported soft Q1 22 numbers, missing estimates across the board and sending the stock down >15%.
Sales were down 6.4% on an organic basis, attributable to acute care therapies (-14.3%) and supply chain challenges. The impact of multiple headwinds was felt on operating margins too (-350bps).
Encouragingly, the FY 22 outlook (upper end of 4-6% organic growth) was maintained.
We will be trimming our estimates to factor in the soft Q1 showing, which should be partly offset by stronger H2 ....